Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections

Recurrent Urinary Tract Infection Clinical Trial

Official title:

Intravesical Antibiotic Instillations Versus Oral Suppression for the Treatment of Recurrent Urinary Tract Infections in Post-menopausal Women

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04285320
• Other study ID #: 1565199
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: March 2021
• Est. completion date: April 2023

Study information

• Verified date: January 2021
• Source: Atlantic Health System
• Contact: Caroline Sabatino, MPH
• Phone: 973-971-7361
• Email: caroline.sabatino[@]atlantichealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a research study that aims to determine if antibiotic bladder instillations (placing an antibiotic directly into the bladder) over several sessions at the office is a good option to prevent recurrent urinary tract infections, in comparison with oral suppression therapy (taking daily antibiotics in the form of pills by mouth). Oral antibiotic suppression therapy is currently the most common treatment route for recurrent urinary tract infections in post-menopausal women. The bladder antibiotic instillation may overcome the disadvantages of oral suppression therapy such as antibiotic resistance, certain side effects, and recurrence of infections after finishing the treatment course.

Description:

In this study, the investigators aim to determine the effectiveness of intra-vesical antibiotic instillations for the prophylactic treatment of recurrent urinary tract infections in menopausal women in comparison with oral suppressive therapy. This is a parallel un-blinded randomized-controlled trial. the investigators will randomize post-menopausal women with recurrent urinary tract infections to either receive 6-8 intra-vesical antibiotic instillations at the office or to receive 3 months of oral antibiotic suppressive therapy. In the bladder instillation arm, based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol: - Amikacin-30 mg in 60 ml of sterile water - Gentamycin-80mg in 60ml sterile water - Tobramycin-80 mg in 100 ml of sterile water In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile: - Trimethoprim daily (100 mg) - Trimethoprim/sulfamethoxazole daily (40 mg/200 mg) - Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg) - Nitrofurantoin monohydrate/macrocrystals daily (50 mg) - Nitrofurantoin monohydrate/macrocrystals daily (100 mg) - Cephalexin daily (125 mg) - Cephalexin daily (250 mg) - Fosfomycin every 10 days (3 grams) All medications used in this study are approved by the FDA to treat urinary tract infections. Participants will be followed for total of 3 months after finishing either treatment course by only reviewing their medical records to collect data regarding development of urinary tract infections after treatment. Primary endpoint/outcome: • To compare the number of women developing urinary tract infections during the 3 months following treatment between the two groups. Secondary endpoints/outcomes: - To compare the rate of antibiotic resistance of isolated pathogens after intravesical antibiotic instillation vs. oral antibiotic suppressive therapy - To compare side effects of the two treatment modalities

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: April 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Post-menopausal women with recurrent urinary tract infections (2 infections in a 6-month period or at least 3 infections in a 1-year period)
• Receiving estrogen vaginal therapy for 1 month prior to enrollment
• Able to come in to the office twice weekly for 3-4 weeks
• English speaking
• No allergy to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.
• No uro-pathogen resistance to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.

Exclusion Criteria:

• Allergy to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
• Recent Urine culture with pathogens resistant to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
• Renal failure (Creatinine clearance <30ml/min)
• History of urinary retention
• History of genitourinary structural abnormalities

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Recurrent Urinary Tract Infection
• Urinary Tract Infections

Intervention

Drug:
• Intravesical antibiotic instillation
Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol: Amikacin-30 mg in 60 ml of sterile water Gentamycin-80mg in 60ml sterile water Tobramycin-80 mg in 100 ml of sterile water
• Antibiotic oral suppressive therapy
In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile: Trimethoprim daily (100 mg) Trimethoprim/sulfamethoxazole daily (40 mg/200 mg) Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg) Nitrofurantoin monohydrate/macrocrystals daily (50 mg) Nitrofurantoin monohydrate/macrocrystals daily (100 mg) Cephalexin daily (125 mg) Cephalexin daily (250 mg) Fosfomycin every 10 days (3 grams)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Atlantic Health System

References & Publications (1)

Chernyak S, Salamon C. Intravesical Antibiotic Administration in the Treatment of Recurrent Urinary Tract Infections: Promising Results From a Case Series. Female Pelvic Med Reconstr Surg. 2020 Feb;26(2):152-154. doi: 10.1097/SPV.0000000000000810. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of participants with urinary tract infections following treatment course	To compare the percentage of women developing urinary tract infections during the 3 months following treatment between the two groups.	Assessed starting immediately after the treatment is completed for a total of 3 months.
Secondary	The rate of antibiotic resistance of pathogens in participants developing urinary tract infections after completing the treatment course.	To compare the rate of antibiotic resistance of isolated pathogens when participants develop a urinary tract infection during the 3 months follow up period after intra-vesical antibiotic instillation vs. oral antibiotic suppressive therapy. the percentage of antibiotics on the susceptibility list of urine cultures will be compared between participants developing urinary tract infection in each group during the 3 months follow-up period after completing the treatment.	Assessed starting immediately after the treatment is completed for a total of 3 months
Secondary	the percentage of patients developing side effects of the 2 treatments	To compare the percentage of patients developing side effects between the two treatment modalities. At their routine follow up visits patients will be asked about whether or not they developed side effects and the type and severity of side effects of the treatment received. The percentage of patients developing side effects (per type and severity) in each arm will be compared.	From the date of randomization until the date of first documented side effect assessed up to 3 months after the treatment is completed in each arm